Glioblastoma stem cells express non‐canonical proteins and exclusive mesenchymal‐like or non‐mesenchymal‐like protein signatures
Sign Up to like & getrecommendations! Published in 2022 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13355
Abstract: Glioblastoma’s (GBM) origin, recurrence and resistance to treatment are driven by GBM cancer stem cells (GSCs). Existing transcriptomic characterisations of GBM classify the tumours to three subtypes: classical, proneural, and mesenchymal. The comprehension of how… read more here.
Keywords: non mesenchymal; mesenchymal like; like protein; gscs ... See more keywords
Abstract 430: Pemigatinib, an FGFR inhibitor, overcomes resistance to KRASG12C inhibitors in mesenchymal-like NSCLC tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-430
Abstract: KRAS is one of the most frequently mutated oncogenes. Clinical studies with recently developed covalent KRASG12C inhibitors have shown promising anticancer activity in patients with KRASG12C tumors (substitution of glycine to cysteine at amino acid… read more here.
Keywords: expression; mesenchymal like; krasg12c inhibitors; krasg12c ... See more keywords
Fzd2 contributes to breast cancer cell mesenchymal-like stemness and drug resistance.
Sign Up to like & getrecommendations! Published in 2020 at "Oncology research"
DOI: 10.3727/096504020x15783052025051
Abstract: Cancer cell stemness is responsible for cancer relapse, distal metastasis, and drug resistance. Herewe identified that Frizzled 2 (Fzd2), one member of Wnt receptor Frizzled family, induced humanbreast cancer (BC) cell stemness via non-canonical Wnt… read more here.
Keywords: cancer; mesenchymal like; drug resistance; fzd2 contributes ... See more keywords